From the Guidelines
Lisdexamfetamine (Vyvanse) does not have a specific street name when used for the treatment of Binge Eating Disorder (BED). While it is known that stimulant medications like Vyvanse may have street names when misused recreationally, such as "study buddies," "smart pills," or "uppers" 1, there isn't a specific street term for Vyvanse when prescribed legitimately for BED treatment. The American Psychiatric Association recommends that patients with binge-eating disorder be treated with eating disorder-focused cognitive-behavioral therapy or interpersonal therapy, and suggests that adults with binge-eating disorder who prefer medication or have not responded to psychotherapy alone be treated with either an antidepressant medication or lisdexamfetamine 1. Some key points to consider when prescribing Vyvanse for BED include:
- Starting doses typically begin at 30mg daily and may increase to 50-70mg daily based on patient response and tolerance.
- The mechanism of action involves regulating dopamine levels in the brain to control impulsive eating behaviors and reduce binge eating episodes.
- Patients should be aware that Vyvanse is a controlled substance with potential for dependence and should only be used under medical supervision.
- Common side effects may include insomnia, decreased appetite, anxiety, and increased heart rate.
- Vyvanse should be part of a comprehensive treatment approach that includes psychological therapy to address the underlying causes of binge eating behavior, as recommended by the American Psychiatric Association 1.
From the Research
Street Name for Lisdexamphetamine (Vyvanse) for BED
- There is no specific street name mentioned in the provided studies for Lisdexamphetamine (Vyvanse) in the context of Binge Eating Disorder (BED) 2, 3, 4, 5, 6.
Lisdexamphetamine (Vyvanse) for BED
- Lisdexamphetamine (Vyvanse) is approved by the FDA for the treatment of moderate to severe BED in adults 2, 3, 4, 5, 6.
- The recommended dose range for Lisdexamphetamine (Vyvanse) in treating BED is 50-70 mg/day 2, 4, 6.
- Studies have shown that Lisdexamphetamine (Vyvanse) significantly reduces binge eating days per week and body weight in patients with BED 2, 3, 4, 6.
Safety and Efficacy
- Lisdexamphetamine (Vyvanse) has been found to be generally well-tolerated in clinical trials, with common adverse events including dry mouth, headache, and insomnia 2, 4, 6.
- The number needed to treat (NNT) for response to Lisdexamphetamine (Vyvanse) was found to be 3, and the number needed to harm (NNH) for discontinuation due to adverse events was 44 6.